A Study of Motexafin Gadolinium for the Treatment of Relapsed or Refractory Multiple Myeloma

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to determine if the drug motexafin gadolinium will be an effective treatment for patients who have relapsed or refractory multiple myeloma.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pharmacyclics LLC.
• Treatments: Motexafin gadolinium

Criteria

Inclusion Criteria:

• Relapsed or Refractory Multiple Myeloma

• ≥ 18 years old

• Able to provide consent for participation

• ECOG status 0-2

Lab values:

• ANC ≥ 1,000/µL

• WBC count ≥ 2.0/µL

• Hemoglobin ≥ 8.0 g/dL

• Platelet count ≥ 50,000/µL

• AST and ALT ≤ 2 x ULN

• Total Bilirubin ≤ 2 x ULN

• Creatinine ≤ 2.0 mg/dL

and

• Not pregnant or lactating